Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery

被引:521
作者
Ito, Tomoki [1 ,2 ]
Hanabuchi, Shino [1 ,2 ]
Wang, Yi-Hong [1 ,2 ]
Park, Woong Ryeon [1 ,2 ]
Arima, Kazuhiko [1 ,2 ]
Bover, Laura [1 ,2 ]
Qin, F. Xiao-Feng [1 ,2 ]
Gilliet, Michel [1 ,2 ]
Liu, Yong-Jun [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Ctr Canc Immunol Res, Houston, TX 77030 USA
关键词
D O I
10.1016/j.immuni.2008.03.018
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Previous studies suggest that thymus produces a homogenous population of natural regulatory T (Treg) cells that express a transcriptional factor FOXP3 and control autoimmunity through a cell-contact-dependent mechanism. We found two subsets of FOXP3(+) natural Treg cells defined by the expression of the costimulatory molecule ICOS in the human thym us and periphery. Whereas the ICOS(+)FOXP3(+) Treg cells used interleukin-10 to suppress dendritic cell function and transforming growth factor (TGF)-beta to suppress T cell function, the ICOS(-)FOXP3(+) Treg cells used TGF-beta only. The survival and proliferation of the two subsets of Treg cells were differentially regulated by signaling through ICOS or CD28, respectively. We suggest that the selection of natural Treg cells in thymus is coupled with Treg cell differentiation into two subsets imprinted with different cytokine expression potentials and use both cell-contact-dependent and independent mechanisms for immunosuppression in periphery.
引用
收藏
页码:870 / 880
页数:11
相关论文
共 56 条
[1]
Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745
[2]
Macrophage-derived chemokine and EBI1-ligand chemokine attract human thymocytes in different stage of development and are produced by distinct subsets of medullary epithelial cells: Possible implications for negative selection [J].
Annunziato, F ;
Romagnani, P ;
Cosmi, L ;
Beltrame, C ;
Steiner, BH ;
Lazzeri, E ;
Raport, CJ ;
Galli, G ;
Manetti, R ;
Mavilia, C ;
Vanini, V ;
Chantry, D ;
Maggi, E ;
Romagnani, S .
JOURNAL OF IMMUNOLOGY, 2000, 165 (01) :238-246
[3]
Phenotype, localization, and mechanism of suppression of CD4+CD25+ human thymocytes [J].
Annunziato, F ;
Cosmi, L ;
Liotta, F ;
Lazzeri, E ;
Manetti, R ;
Vanini, V ;
Romagnani, P ;
Maggi, E ;
Romagnani, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (03) :379-387
[4]
Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells [J].
Aschenbrenner, Katharina ;
D'Cruz, Louise M. ;
Vollmann, Elisabeth H. ;
Hinterberger, Maria ;
Emmerich, Jan ;
Swee, Lee Kim ;
Rolink, Antonius ;
Klein, Ludger .
NATURE IMMUNOLOGY, 2007, 8 (04) :351-358
[5]
Interleukin 10 is a growth factor for a population of regulatory T cells [J].
Asseman, C ;
Powrie, F .
GUT, 1998, 42 (02) :157-158
[6]
An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation [J].
Asseman, C ;
Mauze, S ;
Leach, MW ;
Coffman, RL ;
Powrie, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (07) :995-1003
[7]
HIGH-LEVELS OF INTERLEUKIN-10 PRODUCTION IN-VIVO ARE ASSOCIATED WITH TOLERANCE IN SCID PATIENTS TRANSPLANTED WITH HLA MISMATCHED HEMATOPOIETIC STEM-CELLS [J].
BACCHETTA, R ;
BIGLER, M ;
TOURAINE, JL ;
PARKMAN, R ;
TOVO, PA ;
ABRAMS, J ;
MALEFYT, RD ;
DEVRIES, JE ;
RONCAROLO, MG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (02) :493-502
[8]
MHC class II expression identifies functionally distinct human regulatory T cells [J].
Baecher-Allan, Clare ;
Wolf, Elizabeth ;
Haller, David A. .
JOURNAL OF IMMUNOLOGY, 2006, 176 (08) :4622-4631
[9]
CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity [J].
Belkaid, Y ;
Piccirillo, CA ;
Mendez, S ;
Shevach, EM ;
Sacks, DL .
NATURE, 2002, 420 (6915) :502-507
[10]
Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4+25+ immunoregulatory T cells [J].
Bensinger, SJ ;
Bandeira, A ;
Jordan, MS ;
Caton, AJ ;
Laufer, TM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (04) :427-438